Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy.

Literature DB >> 28102146

Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy.

Aiden Haghikia¹, Calliope A Dendrou², Ruth Schneider¹, Thomas Grüter¹, Thomas Postert³, Mike Matzke⁴, Heike Stephanik⁴, Lars Fugger², Ralf Gold⁵.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2017 PMID： 28102146 DOI： 10.1016/S1474-4422(16)30382-9

Source DB: PubMed Journal: Lancet Neurol ISSN： 1474-4422 Impact factor: 44.182

Keyword Cloud
Cited

× No keyword cloud information.

25 in total

1. Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.

Authors: Jessica Frau; Francesco Saccà; Alessio Signori; Damiano Baroncini; Giuseppe Fenu; Pietro Annovazzi; Marco Capobianco; Elisabetta Signoriello; Alice Laroni; Sara La Gioia; Arianna Sartori; Giorgia Teresa Maniscalco; Simona Bonavita; Marinella Clerico; Cinzia Valeria Russo; Antonio Gallo; Caterina Lapucci; Antonio Carotenuto; Maria Pia Sormani; Eleonora Cocco
Journal: J Neurol Date: 2019-06-17 Impact factor: 4.849

2. Stabilization Without Rituximab After Disease Activation in an Alemtuzumab-Treated Patient with Multiple Sclerosis and a Literature Overview.

Authors: Chantal Kahovec; Michael C Levin
Journal: Int J MS Care Date: 2019 May-Jun

Review 3. Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis.

Authors: Babak Soleimani; Katy Murray; David Hunt
Journal: Drug Saf Date: 2019-08 Impact factor: 5.606

4. Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab.

Authors: David Baker; Samuel S Herrod; Cesar Alvarez-Gonzalez; Gavin Giovannoni; Klaus Schmierer
Journal: JAMA Neurol Date: 2017-08-01 Impact factor: 18.302

5. Product review on MAbs (alemtuzumab and ocrelizumab) for the treatment of multiple sclerosis.

Authors: Tereza Gabelić; Barbara Barun; Ivan Adamec; Magdalena Krbot Skorić; Mario Habek
Journal: Hum Vaccin Immunother Date: 2021-10-20 Impact factor: 4.526

Review 6. Managing Risks with Immune Therapies in Multiple Sclerosis.

Authors: Moritz Förster; Patrick Küry; Orhan Aktas; Clemens Warnke; Joachim Havla; Reinhard Hohlfeld; Jan Mares; Hans-Peter Hartung; David Kremer
Journal: Drug Saf Date: 2019-05 Impact factor: 5.606

Review 7. [Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)].

Authors: Heinz Wiendl; Ralf Gold; Thomas Berger; Tobias Derfuss; Ralf Linker; Mathias Mäurer; Martin Stangel; Orhan Aktas; Karl Baum; Martin Berghoff; Stefan Bittner; Andrew Chan; Adam Czaplinski; Florian Deisenhammer; Franziska Di Pauli; Renaud Du Pasquier; Christian Enzinger; Elisabeth Fertl; Achim Gass; Klaus Gehring; Claudio Gobbi; Norbert Goebels; Michael Guger; Aiden Haghikia; Hans-Peter Hartung; Fedor Heidenreich; Olaf Hoffmann; Zoë R Hunter; Boris Kallmann; Christoph Kleinschnitz; Luisa Klotz; Verena Leussink; Fritz Leutmezer; Volker Limmroth; Jan D Lünemann; Andreas Lutterotti; Sven G Meuth; Uta Meyding-Lamadé; Michael Platten; Peter Rieckmann; Stephan Schmidt; Hayrettin Tumani; Martin S Weber; Frank Weber; Uwe K Zettl; Tjalf Ziemssen; Frauke Zipp
Journal: Nervenarzt Date: 2021-07-23 Impact factor: 1.214